Limits...
Serum Levels of Soluble ST2 and IL-10 Are Associated with Disease Severity in Patients with IgA Nephropathy

View Article: PubMed Central - PubMed

ABSTRACT

Background. The IL-33/ST2 axis is involved in humoral immune responses. Method. The concentrations of sera IL-33 and sST2 in 74 patients and 34 healthy controls (HC) were measured by ELISA. Clinical and laboratory data were examined. The potential association between sera IL-33 and sST2 and the clinical parameters in IgAN patients were analyzed. Results. No difference was discovered in IL-33 concentrations between IgAN patients and HCs; however, the sST2 were significantly higher in each stage of IgAN progression than in the HC. The concentration of sST2 was positively correlated with IL-33 levels in IgAN patients. Higher levels of sera IL-2, IL-4, IL-10, IL-17A, and IFN-γ were detected in patients compared to the HC. The concentration of serum sST2 was positively correlated with the levels of IL-10 in IgAN patients. Furthermore, serum sST2 was negatively correlated with the values of eGFR and serum calcium. Serum sST2 was positively correlated with 24-hour urinary protein, serum phosphorus, and serum IgA; however, serum IL-33 was not associated with these. Following treatment, serum sST2 was significantly decreased, while sera IL-4 and IL-10 were significantly increased. Conclusions. Increased sST2 and IL-10 but not IL-33 may be involved in the pathogenic process of IgAN.

No MeSH data available.


Correlation analysis of serum sST2 with the levels of IL-10 in different stages of IgAN patients. The potential relationships between serum sST2 and the levels of IL-10 in the different stages of IgAN patients were analyzed by Spearman correlation tests. Data shown are the mean concentration of individual subjects from two separate experiments. ((a)–(c)) Serum sST2 was positively correlated with the levels of IL-10 in Stage I+II, Stage III, and Stage IV+V of IgAN patients, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC5120178&req=5

fig6: Correlation analysis of serum sST2 with the levels of IL-10 in different stages of IgAN patients. The potential relationships between serum sST2 and the levels of IL-10 in the different stages of IgAN patients were analyzed by Spearman correlation tests. Data shown are the mean concentration of individual subjects from two separate experiments. ((a)–(c)) Serum sST2 was positively correlated with the levels of IL-10 in Stage I+II, Stage III, and Stage IV+V of IgAN patients, respectively.

Mentions: Since Figure 5(a) showed that serum sST2 was positively correlated with IL-10 levels (r = 0.4796, p = 0.0013), we further analyzed the correlations between serum sST2 and the levels of IL-10 in different stages of IgAN patients. We discovered that serum sST2 was positively correlated with the levels of IL-10 in Stage I+II (r = 0.4576, p = 0.0126, Figure 6(a)), Stage III (r = 0.4153, p = 0.0251, Figure 6(b)), and Stage IV+V (r = 0.4982, p = 0.0299, Figure 6(c)) of IgAN patients.


Serum Levels of Soluble ST2 and IL-10 Are Associated with Disease Severity in Patients with IgA Nephropathy
Correlation analysis of serum sST2 with the levels of IL-10 in different stages of IgAN patients. The potential relationships between serum sST2 and the levels of IL-10 in the different stages of IgAN patients were analyzed by Spearman correlation tests. Data shown are the mean concentration of individual subjects from two separate experiments. ((a)–(c)) Serum sST2 was positively correlated with the levels of IL-10 in Stage I+II, Stage III, and Stage IV+V of IgAN patients, respectively.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC5120178&req=5

fig6: Correlation analysis of serum sST2 with the levels of IL-10 in different stages of IgAN patients. The potential relationships between serum sST2 and the levels of IL-10 in the different stages of IgAN patients were analyzed by Spearman correlation tests. Data shown are the mean concentration of individual subjects from two separate experiments. ((a)–(c)) Serum sST2 was positively correlated with the levels of IL-10 in Stage I+II, Stage III, and Stage IV+V of IgAN patients, respectively.
Mentions: Since Figure 5(a) showed that serum sST2 was positively correlated with IL-10 levels (r = 0.4796, p = 0.0013), we further analyzed the correlations between serum sST2 and the levels of IL-10 in different stages of IgAN patients. We discovered that serum sST2 was positively correlated with the levels of IL-10 in Stage I+II (r = 0.4576, p = 0.0126, Figure 6(a)), Stage III (r = 0.4153, p = 0.0251, Figure 6(b)), and Stage IV+V (r = 0.4982, p = 0.0299, Figure 6(c)) of IgAN patients.

View Article: PubMed Central - PubMed

ABSTRACT

Background. The IL-33/ST2 axis is involved in humoral immune responses. Method. The concentrations of sera IL-33 and sST2 in 74 patients and 34 healthy controls (HC) were measured by ELISA. Clinical and laboratory data were examined. The potential association between sera IL-33 and sST2 and the clinical parameters in IgAN patients were analyzed. Results. No difference was discovered in IL-33 concentrations between IgAN patients and HCs; however, the sST2 were significantly higher in each stage of IgAN progression than in the HC. The concentration of sST2 was positively correlated with IL-33 levels in IgAN patients. Higher levels of sera IL-2, IL-4, IL-10, IL-17A, and IFN-γ were detected in patients compared to the HC. The concentration of serum sST2 was positively correlated with the levels of IL-10 in IgAN patients. Furthermore, serum sST2 was negatively correlated with the values of eGFR and serum calcium. Serum sST2 was positively correlated with 24-hour urinary protein, serum phosphorus, and serum IgA; however, serum IL-33 was not associated with these. Following treatment, serum sST2 was significantly decreased, while sera IL-4 and IL-10 were significantly increased. Conclusions. Increased sST2 and IL-10 but not IL-33 may be involved in the pathogenic process of IgAN.

No MeSH data available.